EMEA (Europe, Middle East and Africa) Oncology/Anti-Cancer Drugs Market Report 2017

October 2017 | 109 pages | ID: EC7EA6B87E6WEN
QYResearch

Abstracts

In this report, the EMEA Oncology/Anti-Cancer Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Oncology/Anti-Cancer Drugs for these regions, from 2012 to 2022 (forecast)

• Europe: Germany, France, UK, Russia, Italy and Benelux;
• Middle East: Saudi Arabia, Israel, UAE and Iran;
• Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Oncology/Anti-Cancer Drugs market competition by top manufacturers/players, with Oncology/Anti-Cancer Drugs sales volume (K Units), price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including

• Amgen
• AstraZeneca
• Roche Diagnostics
• GlaxoSmithKline
• Merck
• Novartis
• AbbVie
• Sanofi
• EIMC United Pharmaceuticals
• Actavis

On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into

• Chemotherapy
• Targeted Therapy
• Immunotherapy (Biologic Therapy)
• Hormonal Therapy
• Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Oncology/Anti-Cancer Drugs for each application, including

• Blood Cancer (Leukaemia)
• Breast Cancer
• Gastrointestinal Cancer
• Respiratory/Lung Cancer
• Skin Cancer
• Other Cancers

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

EMEA (Europe, Middle East and Africa) Oncology/Anti-Cancer Drugs Market Report 2017

1 ONCOLOGY/ANTI-CANCER DRUGS OVERVIEW

1.1 Product Overview and Scope of Oncology/Anti-Cancer Drugs
1.2 Classification of Oncology/Anti-Cancer Drugs
  1.2.1 EMEA Oncology/Anti-Cancer Drugs Market Size (Sales) Comparison by Type (2012-2022)
  1.2.2 EMEA Oncology/Anti-Cancer Drugs Market Size (Sales) Market Share by Type (Product Category) in 2016
  1.2.3 Chemotherapy
  1.2.4 Targeted Therapy
  1.2.5 Immunotherapy (Biologic Therapy)
  1.2.6 Hormonal Therapy
  1.2.7 Others
1.3 EMEA Oncology/Anti-Cancer Drugs Market by Application/End Users
  1.3.1 EMEA Oncology/Anti-Cancer Drugs Sales (Volume) and Market Share Comparison by Application (2012-2022
  1.3.2 Blood Cancer (Leukaemia)
  1.3.3 Breast Cancer
  1.3.4 Gastrointestinal Cancer
  1.3.5 Respiratory/Lung Cancer
  1.3.6 Skin Cancer
  1.3.7 Other Cancers
1.4 EMEA Oncology/Anti-Cancer Drugs Market by Region
  1.4.1 EMEA Oncology/Anti-Cancer Drugs Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 Europe Status and Prospect (2012-2022)
  1.4.3 Middle East Status and Prospect (2012-2022)
  1.4.4 Africa Status and Prospect (2012-2022)
1.5 EMEA Market Size (Value and Volume) of Oncology/Anti-Cancer Drugs (2012-2022)
  1.5.1 EMEA Oncology/Anti-Cancer Drugs Sales and Growth Rate (2012-2022)
  1.5.2 EMEA Oncology/Anti-Cancer Drugs Revenue and Growth Rate (2012-2022)

2 EMEA ONCOLOGY/ANTI-CANCER DRUGS COMPETITION BY MANUFACTURERS/PLAYERS/SUPPLIERS, REGION, TYPE AND APPLICATION

2.1 EMEA Oncology/Anti-Cancer Drugs Market Competition by Players/Manufacturers
  2.1.1 EMEA Oncology/Anti-Cancer Drugs Sales Volume and Market Share of Major Players (2012-2017)
  2.1.2 EMEA Oncology/Anti-Cancer Drugs Revenue and Share by Players (2012-2017)
  2.1.3 EMEA Oncology/Anti-Cancer Drugs Sale Price by Players (2012-2017)
2.2 EMEA Oncology/Anti-Cancer Drugs (Volume and Value) by Type/Product Category
  2.2.1 EMEA Oncology/Anti-Cancer Drugs Sales and Market Share by Type (2012-2017)
  2.2.2 EMEA Oncology/Anti-Cancer Drugs Revenue and Market Share by Type (2012-2017)
  2.2.3 EMEA Oncology/Anti-Cancer Drugs Sale Price by Type (2012-2017)
2.3 EMEA Oncology/Anti-Cancer Drugs (Volume) by Application
2.4 EMEA Oncology/Anti-Cancer Drugs (Volume and Value) by Region
  2.4.1 EMEA Oncology/Anti-Cancer Drugs Sales and Market Share by Region (2012-2017)
  2.4.2 EMEA Oncology/Anti-Cancer Drugs Revenue and Market Share by Region (2012-2017)
  2.4.3 EMEA Oncology/Anti-Cancer Drugs Sales Price by Region (2012-2017)

3 EUROPE ONCOLOGY/ANTI-CANCER DRUGS (VOLUME, VALUE AND SALES PRICE), BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

3.1 Europe Oncology/Anti-Cancer Drugs Sales and Value (2012-2017)
  3.1.1 Europe Oncology/Anti-Cancer Drugs Sales Volume and Growth Rate (2012-2017)
  3.1.2 Europe Oncology/Anti-Cancer Drugs Revenue and Growth Rate (2012-2017)
3.2 Europe Oncology/Anti-Cancer Drugs Sales and Market Share by Type
3.3 Europe Oncology/Anti-Cancer Drugs Sales and Market Share by Application
3.4 Europe Oncology/Anti-Cancer Drugs Sales Volume and Value (Revenue) by Countries
  3.4.1 Europe Oncology/Anti-Cancer Drugs Sales Volume by Countries (2012-2017)
  3.4.2 Europe Oncology/Anti-Cancer Drugs Revenue by Countries (2012-2017)
  3.4.3 Germany Oncology/Anti-Cancer Drugs Sales and Growth Rate (2012-2017)
  3.4.4 France Oncology/Anti-Cancer Drugs Sales and Growth Rate (2012-2017)
  3.4.5 UK Oncology/Anti-Cancer Drugs Sales and Growth Rate (2012-2017)
  3.4.6 Russia Oncology/Anti-Cancer Drugs Sales and Growth Rate (2012-2017)
  3.4.7 Italy Oncology/Anti-Cancer Drugs Sales and Growth Rate (2012-2017)
  3.4.8 Benelux Oncology/Anti-Cancer Drugs Sales and Growth Rate (2012-2017)

4 MIDDLE EAST ONCOLOGY/ANTI-CANCER DRUGS (VOLUME, VALUE AND SALES PRICE), BY REGION, TYPE AND APPLICATION

4.1 Middle East Oncology/Anti-Cancer Drugs Sales and Value (2012-2017)
  4.1.1 Middle East Oncology/Anti-Cancer Drugs Sales Volume and Growth Rate (2012-2017)
  4.1.2 Middle East Oncology/Anti-Cancer Drugs Revenue and Growth Rate (2012-2017)
4.2 Middle East Oncology/Anti-Cancer Drugs Sales and Market Share by Type
4.3 Middle East Oncology/Anti-Cancer Drugs Sales and Market Share by Application
4.4 Middle East Oncology/Anti-Cancer Drugs Sales Volume and Value (Revenue) by Countries
  4.4.1 Middle East Oncology/Anti-Cancer Drugs Sales Volume by Countries (2012-2017)
  4.4.2 Middle East Oncology/Anti-Cancer Drugs Revenue by Countries (2012-2017)
  4.4.3 Saudi Arabia Oncology/Anti-Cancer Drugs Sales and Growth Rate (2012-2017)
  4.4.4 Israel Oncology/Anti-Cancer Drugs Sales and Growth Rate (2012-2017)
  4.4.5 UAE Oncology/Anti-Cancer Drugs Sales and Growth Rate (2012-2017)
  4.4.6 Iran Oncology/Anti-Cancer Drugs Sales and Growth Rate (2012-2017)

5 AFRICA ONCOLOGY/ANTI-CANCER DRUGS (VOLUME, VALUE AND SALES PRICE) BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

5.1 Africa Oncology/Anti-Cancer Drugs Sales and Value (2012-2017)
  5.1.1 Africa Oncology/Anti-Cancer Drugs Sales Volume and Growth Rate (2012-2017)
  5.1.2 Africa Oncology/Anti-Cancer Drugs Revenue and Growth Rate (2012-2017)
5.2 Africa Oncology/Anti-Cancer Drugs Sales and Market Share by Type
5.3 Africa Oncology/Anti-Cancer Drugs Sales and Market Share by Application
5.4 Africa Oncology/Anti-Cancer Drugs Sales Volume and Value (Revenue) by Countries
  5.4.1 Africa Oncology/Anti-Cancer Drugs Sales Volume by Countries (2012-2017)
  5.4.2 Africa Oncology/Anti-Cancer Drugs Revenue by Countries (2012-2017)
  5.4.3 South Africa Oncology/Anti-Cancer Drugs Sales and Growth Rate (2012-2017)
  5.4.4 Nigeria Oncology/Anti-Cancer Drugs Sales and Growth Rate (2012-2017)
  5.4.5 Egypt Oncology/Anti-Cancer Drugs Sales and Growth Rate (2012-2017)
  5.4.6 Algeria Oncology/Anti-Cancer Drugs Sales and Growth Rate (2012-2017)

6 EMEA ONCOLOGY/ANTI-CANCER DRUGS MANUFACTURERS/PLAYERS PROFILES AND SALES DATA

6.1 Amgen
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Oncology/Anti-Cancer Drugs Product Type, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Amgen Oncology/Anti-Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 AstraZeneca
  6.2.1 Company Basic Information, Manufacturing Base and Competitors
  6.2.2 Oncology/Anti-Cancer Drugs Product Type, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 AstraZeneca Oncology/Anti-Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Roche Diagnostics
  6.3.1 Company Basic Information, Manufacturing Base and Competitors
  6.3.2 Oncology/Anti-Cancer Drugs Product Type, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Roche Diagnostics Oncology/Anti-Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 GlaxoSmithKline
  6.4.1 Company Basic Information, Manufacturing Base and Competitors
  6.4.2 Oncology/Anti-Cancer Drugs Product Type, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 GlaxoSmithKline Oncology/Anti-Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Merck
  6.5.1 Company Basic Information, Manufacturing Base and Competitors
  6.5.2 Oncology/Anti-Cancer Drugs Product Type, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Merck Oncology/Anti-Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Novartis
  6.6.1 Company Basic Information, Manufacturing Base and Competitors
  6.6.2 Oncology/Anti-Cancer Drugs Product Type, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Novartis Oncology/Anti-Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 AbbVie
  6.7.1 Company Basic Information, Manufacturing Base and Competitors
  6.7.2 Oncology/Anti-Cancer Drugs Product Type, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 AbbVie Oncology/Anti-Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Sanofi
  6.8.1 Company Basic Information, Manufacturing Base and Competitors
  6.8.2 Oncology/Anti-Cancer Drugs Product Type, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Sanofi Oncology/Anti-Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 EIMC United Pharmaceuticals
  6.9.1 Company Basic Information, Manufacturing Base and Competitors
  6.9.2 Oncology/Anti-Cancer Drugs Product Type, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 EIMC United Pharmaceuticals Oncology/Anti-Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Actavis
  6.10.1 Company Basic Information, Manufacturing Base and Competitors
  6.10.2 Oncology/Anti-Cancer Drugs Product Type, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Actavis Oncology/Anti-Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview

7 ONCOLOGY/ANTI-CANCER DRUGS MANUFACTURING COST ANALYSIS

7.1 Oncology/Anti-Cancer Drugs Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Oncology/Anti-Cancer Drugs

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Oncology/Anti-Cancer Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Oncology/Anti-Cancer Drugs Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 EMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET FORECAST (2017-2022)

11.1 EMEA Oncology/Anti-Cancer Drugs Sales, Revenue and Price Forecast (2017-2022)
  11.1.1 EMEA Oncology/Anti-Cancer Drugs Sales and Growth Rate Forecast (2017-2022)
  11.1.2 EMEA Oncology/Anti-Cancer Drugs Revenue and Growth Rate Forecast (2017-2022)
  11.1.3 EMEA Oncology/Anti-Cancer Drugs Price and Trend Forecast (2017-2022)
11.2 EMEA Oncology/Anti-Cancer Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.3 Europe Oncology/Anti-Cancer Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.4 Middle Eastt Oncology/Anti-Cancer Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.5 Africa Oncology/Anti-Cancer Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.6 EMEA Oncology/Anti-Cancer Drugs Sales Forecast by Type (2017-2022)
11.7 EMEA Oncology/Anti-Cancer Drugs Sales Forecast by Application (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Oncology/Anti-Cancer Drugs
Figure EMEA Oncology/Anti-Cancer Drugs Sales Volume (K Units) by Type (2012-2022)
Figure EMEA Oncology/Anti-Cancer Drugs Sales Volume Market Share by Type (Product Category) in 2016
Figure Chemotherapy Product Picture
Figure Targeted Therapy Product Picture
Figure Immunotherapy (Biologic Therapy) Product Picture
Figure Hormonal Therapy Product Picture
Figure Others Product Picture
Figure EMEA Oncology/Anti-Cancer Drugs Sales Volume (K Units) by Application (2012-2022)
Figure EMEA Sales Market Share of Oncology/Anti-Cancer Drugs by Application in 2016
Figure Blood Cancer (Leukaemia) Examples
Table Key Downstream Customer in Blood Cancer (Leukaemia)
Figure Breast Cancer Examples
Table Key Downstream Customer in Breast Cancer
Figure Gastrointestinal Cancer Examples
Table Key Downstream Customer in Gastrointestinal Cancer
Figure Respiratory/Lung Cancer Examples
Table Key Downstream Customer in Respiratory/Lung Cancer
Figure Skin Cancer Examples
Table Key Downstream Customer in Skin Cancer
Figure Other Cancers Examples
Table Key Downstream Customer in Other Cancers
Figure EMEA Oncology/Anti-Cancer Drugs Market Size (Million USD) by Region (2012-2022)
Figure Europe Oncology/Anti-Cancer Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Europe Oncology/Anti-Cancer Drugs Revenue (Million USD) Status and Forecast by Countries
Figure Middle East Oncology/Anti-Cancer Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Middle East Oncology/Anti-Cancer Drugs Revenue (Million USD) Status and Forecast by Countries
Figure Africa Oncology/Anti-Cancer Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Africa Oncology/Anti-Cancer Drugs Revenue (Million USD) Status and Forecast by Countries
Figure EMEA Oncology/Anti-Cancer Drugs Sales Volume and Growth Rate (2012-2022)
Figure EMEA Oncology/Anti-Cancer Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure EMEA Oncology/Anti-Cancer Drugs Market Major Players Product Sales Volume (K Units) (2012-2017)
Table EMEA Oncology/Anti-Cancer Drugs Sales Volume (K Units) of Major Players (2012-2017)
Table EMEA Oncology/Anti-Cancer Drugs Sales Share by Players (2012-2017)
Figure 2016 Oncology/Anti-Cancer Drugs Sales Share by Players
Figure 2017 Oncology/Anti-Cancer Drugs Sales Share by Players
Figure EMEA Oncology/Anti-Cancer Drugs Market Major Players Product Revenue (Million USD) (2012-2017)
Table EMEA Oncology/Anti-Cancer Drugs Revenue (Million USD) by Players (2012-2017)
Table EMEA Oncology/Anti-Cancer Drugs Revenue Share by Players (2012-2017)
Table 2016 EMEA Oncology/Anti-Cancer Drugs Revenue Share by Players
Table 2017 EMEA Oncology/Anti-Cancer Drugs Revenue Share by Players
Table EMEA Oncology/Anti-Cancer Drugs Sale Price (USD/Unit) by Players (2012-2017)
Table EMEA Oncology/Anti-Cancer Drugs Sales (K Units) and Market Share by Type (2012-2017)
Table EMEA Oncology/Anti-Cancer Drugs Sales Share by Type (2012-2017)
Figure Sales Market Share of Oncology/Anti-Cancer Drugs by Type (2012-2017)
Figure EMEA Oncology/Anti-Cancer Drugs Sales Market Share by Type (2012-2017)
Table EMEA Oncology/Anti-Cancer Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
Table EMEA Oncology/Anti-Cancer Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Oncology/Anti-Cancer Drugs by Type in 2016
Table EMEA Oncology/Anti-Cancer Drugs Sale Price (USD/Unit) by Type (2012-2017)
Table EMEA Oncology/Anti-Cancer Drugs Sales (K Units) and Market Share by Application (2012-2017)
Table EMEA Oncology/Anti-Cancer Drugs Sales Share by Application (2012-2017)
Figure Sales Market Share of Oncology/Anti-Cancer Drugs by Application (2012-2017)
Figure EMEA Oncology/Anti-Cancer Drugs Sales Market Share by Application in 2016
Table EMEA Oncology/Anti-Cancer Drugs Sales (K Units) and Market Share by Region (2012-2017)
Table EMEA Oncology/Anti-Cancer Drugs Sales Share by Region (2012-2017)
Figure Sales Market Share of Oncology/Anti-Cancer Drugs by Region (2012-2017)
Figure EMEA Oncology/Anti-Cancer Drugs Sales Market Share in 2016
Table EMEA Oncology/Anti-Cancer Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
Table EMEA Oncology/Anti-Cancer Drugs Revenue Share by Region (2012-2017)
Figure Revenue Market Share of Oncology/Anti-Cancer Drugs by Region (2012-2017)
Figure EMEA Oncology/Anti-Cancer Drugs Revenue Market Share Regions in 2016
Table EMEA Oncology/Anti-Cancer Drugs Sales Price (USD/Unit) by Region (2012-2017)
Figure Europe Oncology/Anti-Cancer Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Europe Oncology/Anti-Cancer Drugs Revenue and Growth Rate (2012-2017)
Table Europe Oncology/Anti-Cancer Drugs Sales (K Units) by Type (2012-2017)
Table Europe Oncology/Anti-Cancer Drugs Market Share by Type (2012-2017)
Figure Europe Oncology/Anti-Cancer Drugs Market Share by Type in 2016
Table Europe Oncology/Anti-Cancer Drugs Sales (K Units) by Application (2012-2017)
Table Europe Oncology/Anti-Cancer Drugs Market Share by Application (2012-2017)
Figure Europe Oncology/Anti-Cancer Drugs Market Share by Application in 2016
Table Europe Oncology/Anti-Cancer Drugs Sales (K Units) by Countries (2012-2017)
Table Europe Oncology/Anti-Cancer Drugs Sales Market Share by Countries (2012-2017)
Figure Europe Oncology/Anti-Cancer Drugs Sales Market Share by Countries (2012-2017)
Figure Europe Oncology/Anti-Cancer Drugs Sales Market Share by Countries in 2016
Table Europe Oncology/Anti-Cancer Drugs Revenue (Million USD) by Countries (2012-2017)
Table Europe Oncology/Anti-Cancer Drugs Revenue Market Share by Countries (2012-2017)
Figure Europe Oncology/Anti-Cancer Drugs Revenue Market Share by Countries (2012-2017)
Figure Europe Oncology/Anti-Cancer Drugs Revenue Market Share by Countries in 2016
Figure Germany Oncology/Anti-Cancer Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure France Oncology/Anti-Cancer Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure UK Oncology/Anti-Cancer Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Russia Oncology/Anti-Cancer Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Italy Oncology/Anti-Cancer Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Benelux Oncology/Anti-Cancer Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Middle East Oncology/Anti-Cancer Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Middle East Oncology/Anti-Cancer Drugs Revenue (Million USD) and Growth Rate (2012-2017)
Table Middle East Oncology/Anti-Cancer Drugs Sales (K Units) by Type (2012-2017)
Table Middle East Oncology/Anti-Cancer Drugs Market Share by Type (2012-2017)
Figure Middle East Oncology/Anti-Cancer Drugs Market Share by Type (2012-2017)
Table Middle East Oncology/Anti-Cancer Drugs Sales (K Units) by Applications (2012-2017)
Table Middle East Oncology/Anti-Cancer Drugs Market Share by Applications (2012-2017)
Figure Middle East Oncology/Anti-Cancer Drugs Sales Market Share by Application in 2016
Table Middle East Oncology/Anti-Cancer Drugs Sales Volume (K Units) by Countries (2012-2017)
Table Middle East Oncology/Anti-Cancer Drugs Sales Volume Market Share by Countries (2012-2017)
Figure Middle East Oncology/Anti-Cancer Drugs Sales Volume Market Share by Countries in 2016
Table Middle East Oncology/Anti-Cancer Drugs Revenue (Million USD) by Countries (2012-2017)
Table Middle East Oncology/Anti-Cancer Drugs Revenue Market Share by Countries (2012-2017)
Figure Middle East Oncology/Anti-Cancer Drugs Revenue Market Share by Countries (2012-2017)
Figure Middle East Oncology/Anti-Cancer Drugs Revenue Market Share by Countries in 2016
Figure Saudi Arabia Oncology/Anti-Cancer Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Israel Oncology/Anti-Cancer Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure UAE Oncology/Anti-Cancer Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Iran Oncology/Anti-Cancer Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Africa Oncology/Anti-Cancer Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Africa Oncology/Anti-Cancer Drugs Revenue (Million USD) and Growth Rate (2012-2017)
Table Africa Oncology/Anti-Cancer Drugs Sales (K Units) by Type (2012-2017)
Table Africa Oncology/Anti-Cancer Drugs Sales Market Share by Type (2012-2017)
Figure Africa Oncology/Anti-Cancer Drugs Sales Market Share by Type (2012-2017)
Figure Africa Oncology/Anti-Cancer Drugs Sales Market Share by Type in 2016
Table Africa Oncology/Anti-Cancer Drugs Sales (K Units) by Application (2012-2017)
Table Africa Oncology/Anti-Cancer Drugs Sales Market Share by Application (2012-2017)
Figure Africa Oncology/Anti-Cancer Drugs Sales Market Share by Application (2012-2017)
Table Africa Oncology/Anti-Cancer Drugs Sales Volume (K Units) by Countries (2012-2017)
Table Africa Oncology/Anti-Cancer Drugs Sales Market Share by Countries (2012-2017)
Figure Africa Oncology/Anti-Cancer Drugs Sales Market Share by Countries (2012-2017)
Figure Africa Oncology/Anti-Cancer Drugs Sales Market Share by Countries in 2016
Table Africa Oncology/Anti-Cancer Drugs Revenue (Million USD) by Countries (2012-2017)
Table Africa Oncology/Anti-Cancer Drugs Revenue Market Share by Countries (2012-2017)
Figure Africa Oncology/Anti-Cancer Drugs Revenue Market Share by Countries (2012-2017)
Figure Africa Oncology/Anti-Cancer Drugs Revenue Market Share by Countries in 2016
Figure South Africa Oncology/Anti-Cancer Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Nigeria Oncology/Anti-Cancer Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Egypt Oncology/Anti-Cancer Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Algeria Oncology/Anti-Cancer Drugs Sales (K Units) and Growth Rate (2012-2017)
Table Amgen Oncology/Anti-Cancer Drugs Basic Information List
Table Amgen Oncology/Anti-Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Amgen Oncology/Anti-Cancer Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Amgen Oncology/Anti-Cancer Drugs Sales Market Share in EMEA (2012-2017)
Figure Amgen Oncology/Anti-Cancer Drugs Revenue Market Share in EMEA (2012-2017)
Table AstraZeneca Oncology/Anti-Cancer Drugs Basic Information List
Table AstraZeneca Oncology/Anti-Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure AstraZeneca Oncology/Anti-Cancer Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure AstraZeneca Oncology/Anti-Cancer Drugs Sales Market Share in EMEA (2012-2017)
Figure AstraZeneca Oncology/Anti-Cancer Drugs Revenue Market Share in EMEA (2012-2017)
Table Roche Diagnostics Oncology/Anti-Cancer Drugs Basic Information List
Table Roche Diagnostics Oncology/Anti-Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Roche Diagnostics Oncology/Anti-Cancer Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Roche Diagnostics Oncology/Anti-Cancer Drugs Sales Market Share in EMEA (2012-2017)
Figure Roche Diagnostics Oncology/Anti-Cancer Drugs Revenue Market Share in EMEA (2012-2017)
Table GlaxoSmithKline Oncology/Anti-Cancer Drugs Basic Information List
Table GlaxoSmithKline Oncology/Anti-Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure GlaxoSmithKline Oncology/Anti-Cancer Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure GlaxoSmithKline Oncology/Anti-Cancer Drugs Sales Market Share in EMEA (2012-2017)
Figure GlaxoSmithKline Oncology/Anti-Cancer Drugs Revenue Market Share in EMEA (2012-2017)
Table Merck Oncology/Anti-Cancer Drugs Basic Information List
Table Merck Oncology/Anti-Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Merck Oncology/Anti-Cancer Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Merck Oncology/Anti-Cancer Drugs Sales Market Share in EMEA (2012-2017)
Figure Merck Oncology/Anti-Cancer Drugs Revenue Market Share in EMEA (2012-2017)
Table Novartis Oncology/Anti-Cancer Drugs Basic Information List
Table Novartis Oncology/Anti-Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Novartis Oncology/Anti-Cancer Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Novartis Oncology/Anti-Cancer Drugs Sales Market Share in EMEA (2012-2017)
Figure Novartis Oncology/Anti-Cancer Drugs Revenue Market Share in EMEA (2012-2017)
Table AbbVie Oncology/Anti-Cancer Drugs Basic Information List
Table AbbVie Oncology/Anti-Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure AbbVie Oncology/Anti-Cancer Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure AbbVie Oncology/Anti-Cancer Drugs Sales Market Share in EMEA (2012-2017)
Figure AbbVie Oncology/Anti-Cancer Drugs Revenue Market Share in EMEA (2012-2017)
Table Sanofi Oncology/Anti-Cancer Drugs Basic Information List
Table Sanofi Oncology/Anti-Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Sanofi Oncology/Anti-Cancer Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Sanofi Oncology/Anti-Cancer Drugs Sales Market Share in EMEA (2012-2017)
Figure Sanofi Oncology/Anti-Cancer Drugs Revenue Market Share in EMEA (2012-2017)
Table EIMC United Pharmaceuticals Oncology/Anti-Cancer Drugs Basic Information List
Table EIMC United Pharmaceuticals Oncology/Anti-Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure EIMC United Pharmaceuticals Oncology/Anti-Cancer Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure EIMC United Pharmaceuticals Oncology/Anti-Cancer Drugs Sales Market Share in EMEA (2012-2017)
Figure EIMC United Pharmaceuticals Oncology/Anti-Cancer Drugs Revenue Market Share in EMEA (2012-2017)
Table Actavis Oncology/Anti-Cancer Drugs Basic Information List
Table Actavis Oncology/Anti-Cancer Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Actavis Oncology/Anti-Cancer Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Actavis Oncology/Anti-Cancer Drugs Sales Market Share in EMEA (2012-2017)
Figure Actavis Oncology/Anti-Cancer Drugs Revenue Market Share in EMEA (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Oncology/Anti-Cancer Drugs
Figure Manufacturing Process Analysis of Oncology/Anti-Cancer Drugs
Figure Oncology/Anti-Cancer Drugs Industrial Chain Analysis
Table Raw Materials Sources of Oncology/Anti-Cancer Drugs Major Manufacturers in 2016
Table Major Buyers of Oncology/Anti-Cancer Drugs
Table Distributors/Traders List
Figure EMEA Oncology/Anti-Cancer Drugs Sales (K Units) and Growth Rate Forecast (2017-2022)
Figure EMEA Oncology/Anti-Cancer Drugs Revenue and Growth Rate Forecast (2017-2022)
Figure EMEA Oncology/Anti-Cancer Drugs Price (USD/Unit) and Trend Forecast (2017-2022)
Table EMEA Oncology/Anti-Cancer Drugs Sales (K Units) Forecast by Region (2017-2022)
Figure EMEA Oncology/Anti-Cancer Drugs Sales Market Share Forecast by Region (2017-2022)
Table EMEA Oncology/Anti-Cancer Drugs Revenue (Million USD) Forecast by Region (2017-2022)
Figure EMEA Oncology/Anti-Cancer Drugs Revenue Market Share Forecast by Region (2017-2022)
Table Europe Oncology/Anti-Cancer Drugs Sales (K Units) Forecast by Countries (2017-2022)
Figure Europe Oncology/Anti-Cancer Drugs Sales Market Share Forecast by Countries (2017-2022)
Table Europe Oncology/Anti-Cancer Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Europe Oncology/Anti-Cancer Drugs Revenue Market Share Forecast by Countries (2017-2022)
Table Middle East Oncology/Anti-Cancer Drugs Sales (K Units) Forecast by Countries (2017-2022)
Figure Middle East Oncology/Anti-Cancer Drugs Sales Market Share Forecast by Countries (2017-2022)
Table Middle East Oncology/Anti-Cancer Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Middle East Oncology/Anti-Cancer Drugs Revenue Market Share Forecast by Countries (2017-2022)
Table Africa Oncology/Anti-Cancer Drugs Sales (K Units) Forecast by Countries (2017-2022)
Figure Africa Oncology/Anti-Cancer Drugs Sales Market Share Forecast by Countries (2017-2022)
Table Africa Oncology/Anti-Cancer Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Africa Oncology/Anti-Cancer Drugs Revenue Market Share Forecast by Countries (2017-2022)
Table EMEA Oncology/Anti-Cancer Drugs Sales (K Units) Forecast by Type (2017-2022)
Figure EMEA Oncology/Anti-Cancer Drugs Sales Market Share Forecast by Type (2017-2022)
Table EMEA Oncology/Anti-Cancer Drugs Sales (K Units) Forecast by Application (2017-2022)
Figure EMEA Oncology/Anti-Cancer Drugs Sales Market Share Forecast by Application (2017-2022)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources